Where current pharmacological therapies fall short in COPD: Symptom control is not enough

European Respiratory Review

Volumn 16, Issue 105, 2007, Pages 98-104

  Roche, N ^a  

^a HÔTEL DIEU   (France)

Author keywords

2 Agonists; Chronic obstructive pulmonary disease; Disease progression; Inflammation; Inhaled corticosteroid

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; SALMETEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EXERCISE TOLERANCE; HUMAN; INFLAMMATION; LONG TERM CARE; LUNG FUNCTION; LUNG SURGERY; MONOTHERAPY; MORTALITY; OXYGEN THERAPY; QUALITY OF LIFE; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME;

EID: 37249001261     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00010503     Document Type: Conference Paper

References (49)

1. Global Initiative for Chronic Obstructive Lung Disease. Executive summary: global strategy for the diagnosis, management, and prevention of COPD, 2006. www.goldcopd.com. Date last updated: November 2006. Date last accessed: June 19, 2007.
2. Weiss ST, DeMeo DL, Postma DS. COPD: problems in diagnosis and measurement. Eur Respir J 2003; 21: Suppl. 41, 4s-12s.
3. National Heart, Lung and Blood Institute. Morbidity and Mortality Chartbook. Bethesda, National Institutes for Health, National Heart, Lung and Blood Institute, 2000.
4. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
5. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
6. Decramer M, De Benedetto F, Del Ponte A, Marinari S. Systemic effects of COPD. Respir Med 2005; 99: Suppl. B, S3-S10.
7. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
8. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 4: CD003793.
9. Rennard SI. Inflammation in COPD: a link to systemic comorbidities. Eur Respir Rev 2007; 16: 91-97.
10. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006; 7: 675-681.
11. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Fan CK. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000; 162: 1355-1360.
12. Roche N, Huchon G. Reducing airways inflammation to prevent exacerbations in chronic obstructive pulmonary disease. Allergy 2005; 60: 1350-1356.
13. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
14. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006; 7: 1-9.
15. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004; 364: 791-802.
16. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4: 253-262.
17. Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001; 18: 903-908.
18. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-342.
19. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
20. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
21. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
22. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
23. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial. Ann Intern Med 1980; 93: 391-398.
24. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679.
25. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14: 1002-1008.
26. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75-81.
27. Sin DD, Man SF. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 624-629.
28. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
29. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-825.
30. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
31. Ferguson GT, Calverley PMA, Anderson JA, et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial. Am J Respir Crit Care Med 2007; 175: A763.
32. Leidy NK. Evolving concepts in the measurement of treatment effects. Proc Am Thorac Soc 2006; 3: 212-217.
33. Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc 2006; 3: 276-280.
34. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58: 654-658.
35. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.
36. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jorres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-220.
37. Hatipoglu U, Laghi F, Tobin MJ. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160: 1916-1921.
38. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832.
39. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
41. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
42. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
43. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
44. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
45. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
46. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817-1824.
47. McIvor RA. Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors. Eur Respir Rev 2007; 16: 105-112.
48. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084-1106.
49. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364: 985-996.